On May 28th, the U.S. Food and Drug Administration (FDA) approved cariprazine for the treatment of depressive episodes in adults with bipolar I disorder. Sold under the brand name Vraylar, the…
Read More
Cariprazine, a medicine approved by the FDA in 2015 for the treatment of manic episodes in bipolar I disorder, was effective in reducing depressive symptoms in bipolar I disorder patients in a phase…
Read More
Light therapy can be an effective treatment for seasonal depression, but there has been concern that the treatment might induce mania in people with bipolar disorder. Participants in the new trial…
Read More
After searching for decades, researchers have discovered important clues about how lithium, a mainstay of treatment for many people with bipolar disorder, alters the function of neurons to prevent…
Read More
Thoughts of suicide in patients with bipolar disorder declined significantly within 24 hours following treatment with ketamine, according to a small randomized trial reported April 28 in the journal…
Read More
